Gabriele Ricci - Takeda Pharmaceutical Chief Officer
| TKPHF Stock | USD 25.91 0.79 3.14% |
Insider
Gabriele Ricci is Chief Officer of Takeda Pharmaceutical Co
| Age | 45 |
| Phone | 81 3 3278 2111 |
| Web | https://www.takeda.com |
Takeda Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.0247 % which means that it generated a profit of $0.0247 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0477 %, meaning that it generated $0.0477 on every $100 dollars invested by stockholders. Takeda Pharmaceutical's management efficiency ratios could be used to measure how well Takeda Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Catherine Levitt | Astellas Pharma | N/A | |
| Masahiko Uchida | Chugai Pharmaceutical Co | N/A | |
| Michael Preuss | Bayer AG | N/A | |
| Rodrigo Santos | Bayer AG | 50 | |
| Collette Taylor | Astellas Pharma | 60 | |
| Barbara Weiland | Merck KGaA ADR | 49 | |
| Stig Ogata | Astellas Pharma | N/A | |
| Minoru Kikuoka | Astellas Pharma | N/A | |
| BerndPeter Bier | Bayer AG | 56 | |
| Friederike Rotsch | Merck KGaA ADR | 51 | |
| Naoto Tsukaguchi | Daiichi Sankyo | N/A | |
| Gabriel Harnier | Bayer AG | 52 | |
| Junichi Onuma | Daiichi Sankyo | N/A | |
| Yoshinori Kaneshima | Daiichi Sankyo | N/A | |
| Gerhard Schmitz | Merck KGaA ADR | 60 | |
| Toshiya Sasai | Chugai Pharmaceutical Co | N/A | |
| Sunao DVM | Daiichi Sankyo | 69 | |
| Katsuyoshi Sugita | Astellas Pharma | N/A | |
| Hideyuki Haruyama | Daiichi Sankyo | N/A | |
| Nobue Yasuda | Astellas Pharma | N/A | |
| Marielle MD | Daiichi Sankyo | N/A | |
Management Performance
| Return On Equity | 0.0477 | |||
| Return On Asset | 0.0247 |
Takeda Pharmaceutical Leadership Team
Elected by the shareholders, the Takeda Pharmaceutical's board of directors comprises two types of representatives: Takeda Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Takeda. The board's role is to monitor Takeda Pharmaceutical's management team and ensure that shareholders' interests are well served. Takeda Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Takeda Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christophe Weber, CEO and President and Representative Director | ||
| Christopher OReilly, Global Fin | ||
| Andrew Plump, Chief Medical and Scientific Officer and Corporate Officer | ||
| Seigo Izumo, Chair Board | ||
| Gabriele Ricci, Chief Officer | ||
| Salvatore Alesci, Member Policy | ||
| Iwaaki Taniguchi, Sr Department | ||
| Constantine Saroukos, CFO Director | ||
| Haruhiko Hirate, Member Board | ||
| Norimasa Takeda, Chief Controller |
Takeda Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Takeda Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0477 | |||
| Return On Asset | 0.0247 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.13 % | |||
| Current Valuation | 75.53 B | |||
| Shares Outstanding | 1.56 B | |||
| Shares Owned By Insiders | 1.20 % | |||
| Shares Owned By Institutions | 41.35 % | |||
| Price To Earning | 27.54 X | |||
| Price To Book | 0.97 X |
Currently Active Assets on Macroaxis
| NVDA | NVIDIA | |
| CRESY | Cresud SACIF y | |
| GOOG | Alphabet Inc Class C | |
| FMC | FMC Corporation | |
| XYF | X Financial Class |
Additional Information and Resources on Investing in Takeda Pink Sheet
When determining whether Takeda Pharmaceutical is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Takeda Pink Sheet is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Takeda Pharmaceutical Co Stock. Highlighted below are key reports to facilitate an investment decision about Takeda Pharmaceutical Co Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Takeda Pharmaceutical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..